Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on November 2, 2004. The report addresses a specific corporate event regarding the amendment of a material definitive agreement related to executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel-related compensation adjustment and does not contain financial performance data.
Material Changes
The material change reported is an amendment to the compensation agreement for James Palmer, the former Chief Scientific Officer, following his death. The Compensation and Management Development Committee made the following determinations:
- Accelerated the vesting of 178,889 shares of restricted stock previously awarded to Dr. Palmer.
- Granted Dr. Palmer full-term participation in Long-Term Performance Awards previously granted to him.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future operations, or discussion of risks and contingencies beyond the specific event reported. There are no unusual items or financial contingencies disclosed in this document.
Investor Verification Checklist
- Verify the total number of shares (178,889) accelerated for vesting.
- Confirm the terms of the Long-Term Performance Awards granted to the estate of the former Chief Scientific Officer.
- Review the company's proxy statement or 10-K for the standard vesting schedules that were amended by this decision.